Study On The Effect Of Sacubitril/Valsartan On Plasma NE And Serum CTnⅠ Levels In Patients With Heart Failure With Reduced Ejection Fraction

ObjectiveTo investigate the changes of plasma norepinephrine(NE),serum cardiac troponin I(c Tn I)and plasma N-terminal precursor B-type natriuretic peptide(NT pro BNP),the changes of cardiac function and the influence of prognosis in patients with heart failure after the treatment of Sacubitril/valsartan.Methods96 patients with heart failure who were hospitalized in the Department of Cardiology of our hospital were selected as the subjects from Sep.2018 to Feb.2019 and were divided into experimental group and control group,48 patients in each group,according to the method of digital random table.The patients on the basis of routine anti heart failure in the two groups were given benazepril hydrochloride in the control group,and patients in the experimental group were given Sacubitril/valsartan.To compare the levels of plasma NE,serum c Tn I,plasma NT pro BNP,cardiac function before and after treatment,the times of re hospitalization in half a year,cumulative hospitalization time,adverse symptoms and adverse cardiac events in the follow-up period.ResultsCompared with before treatment,the plasma NE,serum c Tn I,and NTpro BNP in the two groups of patients showed significant improvement,and the differences were statistically significant(P <0.05).The plasma NE,serum c Tn I,and NT-pro BNP were lower in the experimental group after treatment.In the control group,the difference was statistically significant(P <0.05).On the cardiac ultrasound index,LVEF in the experimental group was higher than that in the control group,and LA and LVEDD were lower than those in the control group.The difference was statistically significant(P <0.05).The 6-minute walking distance between the two groups of patients was significantly higher than that before the treatment,and the difference was statistically significant(P<0.05).The 6-minute walking distance of the experimental group was higher than that of the control group,and the difference was statistically significant(P <0.05).The number of rehospitalizations and cumulative hospitalization time in the experimental group were lower than those in the control group,and the differences were statistically significant(P <0.05).After treatment,the systolic blood pressure,heart rate,body weight,and daily mean daily intake were significantly improved compared with those before treatment,and the differences were statistically significant(P <0.05).After treatment,the systolic blood pressure and average daily intake of the experimental group were compared with the control.The improvement in the group was obvious,and the difference was statistically significant(P <0.05),while the difference in heart rate and weight was not statistically significant(P> 0.05).Comparing the total effective rate of treatment between the two groups of patients,the experimental group was significantly higher,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups of patients(P> 0.05).The cardiovascular disease mortality and rehospitalization rate in the experimental group were lower than those in the control group,and the differences were statistically significant(P<0.05).ConclusionSacubitril/valsartan is used in the treatment of patients with heart failure,which can effectively regulate the levels of plasma NE,serum c Tn I and NTpro BNP,improve cardiac function indicators,improve activity endurance,maintain normal standards such as blood pressure,heart rate,weight,etc.It can reduce the occurrence of adverse cardiac events,has good safety guarantee,significant treatment effect and high application value.